Search

Displaying results 1721 - 1730 of 7018 in total
  1. Drug

    Avibactam

    go.drugbank.com/drugs/DB09060
    ApprovedInvestigational

    Avibactam is a non-β-lactam β-lactamase inhibitor that is available in combination with ceftazidime (Avycaz). … As there is limited clinical safety and efficacy data, Avycaz should be reserved for patients over 18 years old who have limited or not alternative treatment options.

  2. Drug

    Glucosamine

    go.drugbank.com/drugs/DB01296
    Approved

    [A231894,A232289] It is currently not approved as a prescription product by the FDA, but is widely available over the counter. … Glucosamine is commonly used over the counter as a treatment for arthritic joint pain, although its acceptance as a medical therapy varies due to contradictory and findings with unclear clinical significance

    Mixtures: Gel
  3. Drug

    Ofatumumab

    go.drugbank.com/drugs/DB06650
    ApprovedInvestigational

    It is an IgG1κ human monoclonal antibody produced from a recombinant murine cell line (NS0) via transgenic mouse and hybridoma technology. … has a higher affinity towards CD20.

  4. Drug

    Zofenopril

    go.drugbank.com/drugs/DB13166
    ApprovedInvestigational

    Zofenopril is employed as both a cardioprotective and anti-hypertensive agent. It is an angiotensin-converting enzyme (ACE) inhibitor.

  5. Drug

    Bictegravir

    go.drugbank.com/drugs/DB11799
    ApprovedInvestigational

    It has been approved for HIV-1 monotherapy combined with 2 other antiretrovirals in a single tablet.[L43677] … Bictegravir is a recently approved investigational drug that has been used in trials studying the treatment of HIV-1 and HIV-2 infection.

  6. Drug

    Diosmin

    go.drugbank.com/drugs/DB08995
    ApprovedInvestigational

    Diosmin is widely available over-the-counter and demonstrates a favourable a favorable safety profile.[A232890,T840,L33040] … Chronic venous insufficiency is a common condition the western population.

    Mixtures: Hemo Rid CT Tablet
  7. Drug

    Ponatinib

    go.drugbank.com/drugs/DB08901
    ApprovedInvestigational

    Ponatinib is a novel Bcr-Abl tyrosine kinase inhibitor that is especially effective against the T315I mutation for the treatment of chronic myeloid leukemia. FDA approved on December 14, 2012.

    Categories: P-glycoprotein substrates with a Narrow Therapeutic Index, Cytochrome P-450 CYP2C8 Substrates with a Narrow Therapeutic Index
  8. Drug

    Nicergoline

    go.drugbank.com/drugs/DB00699
    Approved

    An ergot derivative that has been used as a cerebral vasodilator and in peripheral vascular disease. It has been suggested to ameliorate cognitive deficits in cerebrovascular disease.

  9. Drug

    Elbasvir

    go.drugbank.com/drugs/DB11574
    Approved

    [A19593] Substitutions at amino acid positions 28, 30, 31, or 93 are known to confer resistance to elbasvir. … Elbasvir is an inhibitor of NS5A, a protein essential for viral replication and virion assembly.

  10. Drug

    Midostaurin

    go.drugbank.com/drugs/DB06595
    ApprovedInvestigational

    It was initially characterized as a potential broad-spectrum antineoplastic agent, with activity toward diverse solid and hematopoietic tumors [A19108]. … Midostaurin (as Rydapt) is a multitarget kinase inhibitor for the treatment for adult patients with newly diagnosed acute myeloid leukemia (AML) who have a specific genetic mutation called FLT3.

    Categories: Cytochrome P-450 CYP3A4 Substrates with a Narrow Therapeutic Index